AXSOME THERAPEUTICS, INC. (AXSM) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30..
Borrowing debt
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | 70.00M USD | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | 117.96M USD | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Total assets | 761.45M USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $70.00M | $117.96M | (m) | (m) | $761.45M | (m) |
| 2026-03-31 | (m) | (m) | $70.00M | $117.85M | (m) | (m) | $713.61M | (m) |
| 2025-12-31 | (m) | (m) | $70.00M | $117.75M | (m) | (m) | $689.80M | (m) |
| 2025-09-30 | (m) | (m) | $70.00M | $117.64M | (m) | (m) | $669.25M | (m) |
| 2025-06-30 | (m) | (m) | $70.00M | $117.54M | (m) | (m) | $639.78M | (m) |
| 2025-03-31 | (m) | (m) | (m) | $181.38M | (m) | (m) | $596.67M | (m) |
| 2024-12-31 | (m) | (m) | (m) | $180.71M | (m) | (m) | $568.50M | (m) |
| 2024-09-30 | (m) | (m) | (m) | $180.00M | (m) | (m) | $561.46M | (m) |
| 2024-06-30 | (m) | (m) | (m) | $179.33M | (m) | (m) | $548.23M | (m) |
| 2024-03-31 | (m) | (m) | (m) | $178.69M | (m) | (m) | $545.73M | (m) |
| 2023-12-31 | (m) | (m) | (m) | $178.07M | (m) | (m) | $588.24M | (m) |
| 2023-09-30 | (m) | (m) | (m) | $177.45M | (m) | (m) | $600.86M | (m) |
| 2023-06-30 | (m) | (m) | (m) | $176.82M | (m) | (m) | $611.64M | (m) |
| 2023-03-31 | (m) | (m) | (m) | $147.62M | (m) | (m) | $389.18M | (m) |
| 2022-12-31 | (m) | (m) | (m) | $94.26M | (m) | (m) | $331.48M | (m) |
| 2022-09-30 | (m) | (m) | (m) | $93.91M | (m) | (m) | $338.96M | (m) |
| 2022-06-30 | (m) | (m) | (m) | $93.46M | (m) | (m) | $180.56M | (m) |
| 2022-03-31 | (m) | (m) | (m) | $49.31M | (m) | (m) | $88.56M | (m) |
| 2021-12-31 | (m) | (m) | (m) | $49.09M | (m) | (m) | $87.79M | (m) |
| 2021-09-30 | (m) | (m) | (m) | $49.17M | (m) | (m) | $116.60M | (m) |
| 2021-06-30 | (m) | (m) | (m) | $48.88M | (m) | (m) | $143.26M | (m) |
| 2021-03-31 | (m) | (m) | (m) | $48.60M | (m) | (m) | $166.90M | (m) |
| 2020-12-31 | (m) | (m) | (m) | $48.32M | (m) | (m) | $186.13M | (m) |
| 2020-09-30 | (m) | (m) | (m) | $48.03M | (m) | (m) | $203.63M | (m) |
| 2020-06-30 | (m) | (m) | $6.55M | $13.74M | (m) | (m) | $190.99M | (m) |
| 2020-03-31 | (m) | (m) | $4.57M | $15.54M | (m) | (m) | $197.80M | (m) |
| 2019-12-31 | (m) | (m) | $2.60M | $17.33M | (m) | (m) | $220.55M | (m) |
| 2019-09-30 | (m) | (m) | $648.52K | $19.11M | (m) | (m) | $44.44M | (m) |
| 2019-06-30 | (m) | (m) | $2.16M | $17.42M | (m) | (m) | $54.78M | (m) |
| 2019-03-31 | (m) | (m) | $535.77K | $18.82M | (m) | (m) | $43.90M | (m) |
| 2018-12-31 | (m) | (m) | $3.29M | $3.62M | (m) | (m) | $15.38M | (m) |
| 2018-09-30 | (m) | (m) | $3.29M | $4.44M | (m) | (m) | $16.13M | (m) |
| 2018-06-30 | (m) | (m) | $3.28M | $5.19M | (m) | (m) | $21.73M | (m) |
| 2018-03-31 | (m) | (m) | $3.28M | $5.93M | (m) | (m) | $27.94M | (m) |
| 2017-12-31 | (m) | (m) | $3.27M | $6.66M | (m) | (m) | $35.56M | (m) |
| 2017-09-30 | (m) | (m) | $2.72M | $7.38M | (m) | (m) | $32.62M | (m) |
| 2017-06-30 | (m) | (m) | $1.90M | $8.08M | (m) | (m) | $39.04M | (m) |
| 2017-03-31 | (m) | (m) | $1.08M | $8.78M | (m) | (m) | $46.41M | (m) |
| 2016-12-31 | (m) | (m) | $269.16K | $9.47M | (m) | (m) | $38.21M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |